Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases

Allen D. Brinker, Ronald T. Wassel, Jenna Lyndly, Jose Serrano, Mark Avigan, William M. Lee, Leonard B. Seeff

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Telithromycin is the first of a new class of ketolide antibiotics with increased activity against penicillin-resistant and erythromycin-resistant pneumococci. This agent received approval by the United States Food and Drug Administration (FDA) in 2004 for treatment of upper and lower respiratory infections. Following market introduction, spontaneous reports of telithromycin-associated hepatotoxicity, including frank liver failure, were received. To address these reports, an ad hoc group with expertise in spontaneous adverse events reporting and experience in evaluating drug-induced liver injury was formed, including members of the FDA, other federal agencies, and academia. The primary objective of this group was to adjudicate case reports of hepatic toxicity for causal attribution to telithromycin. After an initial screening of all cases of liver injury associated with telithromycin reported to FDA as of April 2006 by one of the authors, 42 cases were comprehensively reviewed and adjudicated. Five cases included a severe outcome of either death (n = 4) or liver transplantation (n = 1); more than half were considered highly likely or probable in their causal association with telithromycin. Typical clinical features were: short latency (median, 10 days) and abrupt onset of fever, abdominal pain, and jaundice, sometimes with the presence of ascites even in cases that resolved. Concurrence in assignment of causality increased after agreement on definitions of categories and interactive discussions. Conclusion: Telithromycin is a rare cause of drug-induced liver injury that may have a distinctive clinical signature and associated high mortality rate. Consensus for attribution of liver injury to a selected drug exposure by individual experts can be aided by careful definition of terminology and discussion.

Original languageEnglish (US)
Pages (from-to)250-257
Number of pages8
JournalHepatology
Volume49
Issue number1
DOIs
StatePublished - 2009

Fingerprint

Causality
United States Food and Drug Administration
Chemical and Drug Induced Liver Injury
Liver
Ketolides
Liver Failure
Wounds and Injuries
Erythromycin
Streptococcus pneumoniae
Jaundice
Ascites
Terminology
Respiratory Tract Infections
Penicillins
Liver Transplantation
Abdominal Pain
telithromycin
Fever
Anti-Bacterial Agents
Mortality

ASJC Scopus subject areas

  • Hepatology
  • Medicine(all)

Cite this

Brinker, A. D., Wassel, R. T., Lyndly, J., Serrano, J., Avigan, M., Lee, W. M., & Seeff, L. B. (2009). Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases. Hepatology, 49(1), 250-257. https://doi.org/10.1002/hep.22620

Telithromycin-associated hepatotoxicity : Clinical spectrum and causality assessment of 42 cases. / Brinker, Allen D.; Wassel, Ronald T.; Lyndly, Jenna; Serrano, Jose; Avigan, Mark; Lee, William M.; Seeff, Leonard B.

In: Hepatology, Vol. 49, No. 1, 2009, p. 250-257.

Research output: Contribution to journalArticle

Brinker, AD, Wassel, RT, Lyndly, J, Serrano, J, Avigan, M, Lee, WM & Seeff, LB 2009, 'Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases', Hepatology, vol. 49, no. 1, pp. 250-257. https://doi.org/10.1002/hep.22620
Brinker, Allen D. ; Wassel, Ronald T. ; Lyndly, Jenna ; Serrano, Jose ; Avigan, Mark ; Lee, William M. ; Seeff, Leonard B. / Telithromycin-associated hepatotoxicity : Clinical spectrum and causality assessment of 42 cases. In: Hepatology. 2009 ; Vol. 49, No. 1. pp. 250-257.
@article{a757c12e7a9e4b7082933e5f031c71ab,
title = "Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases",
abstract = "Telithromycin is the first of a new class of ketolide antibiotics with increased activity against penicillin-resistant and erythromycin-resistant pneumococci. This agent received approval by the United States Food and Drug Administration (FDA) in 2004 for treatment of upper and lower respiratory infections. Following market introduction, spontaneous reports of telithromycin-associated hepatotoxicity, including frank liver failure, were received. To address these reports, an ad hoc group with expertise in spontaneous adverse events reporting and experience in evaluating drug-induced liver injury was formed, including members of the FDA, other federal agencies, and academia. The primary objective of this group was to adjudicate case reports of hepatic toxicity for causal attribution to telithromycin. After an initial screening of all cases of liver injury associated with telithromycin reported to FDA as of April 2006 by one of the authors, 42 cases were comprehensively reviewed and adjudicated. Five cases included a severe outcome of either death (n = 4) or liver transplantation (n = 1); more than half were considered highly likely or probable in their causal association with telithromycin. Typical clinical features were: short latency (median, 10 days) and abrupt onset of fever, abdominal pain, and jaundice, sometimes with the presence of ascites even in cases that resolved. Concurrence in assignment of causality increased after agreement on definitions of categories and interactive discussions. Conclusion: Telithromycin is a rare cause of drug-induced liver injury that may have a distinctive clinical signature and associated high mortality rate. Consensus for attribution of liver injury to a selected drug exposure by individual experts can be aided by careful definition of terminology and discussion.",
author = "Brinker, {Allen D.} and Wassel, {Ronald T.} and Jenna Lyndly and Jose Serrano and Mark Avigan and Lee, {William M.} and Seeff, {Leonard B.}",
year = "2009",
doi = "10.1002/hep.22620",
language = "English (US)",
volume = "49",
pages = "250--257",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Telithromycin-associated hepatotoxicity

T2 - Clinical spectrum and causality assessment of 42 cases

AU - Brinker, Allen D.

AU - Wassel, Ronald T.

AU - Lyndly, Jenna

AU - Serrano, Jose

AU - Avigan, Mark

AU - Lee, William M.

AU - Seeff, Leonard B.

PY - 2009

Y1 - 2009

N2 - Telithromycin is the first of a new class of ketolide antibiotics with increased activity against penicillin-resistant and erythromycin-resistant pneumococci. This agent received approval by the United States Food and Drug Administration (FDA) in 2004 for treatment of upper and lower respiratory infections. Following market introduction, spontaneous reports of telithromycin-associated hepatotoxicity, including frank liver failure, were received. To address these reports, an ad hoc group with expertise in spontaneous adverse events reporting and experience in evaluating drug-induced liver injury was formed, including members of the FDA, other federal agencies, and academia. The primary objective of this group was to adjudicate case reports of hepatic toxicity for causal attribution to telithromycin. After an initial screening of all cases of liver injury associated with telithromycin reported to FDA as of April 2006 by one of the authors, 42 cases were comprehensively reviewed and adjudicated. Five cases included a severe outcome of either death (n = 4) or liver transplantation (n = 1); more than half were considered highly likely or probable in their causal association with telithromycin. Typical clinical features were: short latency (median, 10 days) and abrupt onset of fever, abdominal pain, and jaundice, sometimes with the presence of ascites even in cases that resolved. Concurrence in assignment of causality increased after agreement on definitions of categories and interactive discussions. Conclusion: Telithromycin is a rare cause of drug-induced liver injury that may have a distinctive clinical signature and associated high mortality rate. Consensus for attribution of liver injury to a selected drug exposure by individual experts can be aided by careful definition of terminology and discussion.

AB - Telithromycin is the first of a new class of ketolide antibiotics with increased activity against penicillin-resistant and erythromycin-resistant pneumococci. This agent received approval by the United States Food and Drug Administration (FDA) in 2004 for treatment of upper and lower respiratory infections. Following market introduction, spontaneous reports of telithromycin-associated hepatotoxicity, including frank liver failure, were received. To address these reports, an ad hoc group with expertise in spontaneous adverse events reporting and experience in evaluating drug-induced liver injury was formed, including members of the FDA, other federal agencies, and academia. The primary objective of this group was to adjudicate case reports of hepatic toxicity for causal attribution to telithromycin. After an initial screening of all cases of liver injury associated with telithromycin reported to FDA as of April 2006 by one of the authors, 42 cases were comprehensively reviewed and adjudicated. Five cases included a severe outcome of either death (n = 4) or liver transplantation (n = 1); more than half were considered highly likely or probable in their causal association with telithromycin. Typical clinical features were: short latency (median, 10 days) and abrupt onset of fever, abdominal pain, and jaundice, sometimes with the presence of ascites even in cases that resolved. Concurrence in assignment of causality increased after agreement on definitions of categories and interactive discussions. Conclusion: Telithromycin is a rare cause of drug-induced liver injury that may have a distinctive clinical signature and associated high mortality rate. Consensus for attribution of liver injury to a selected drug exposure by individual experts can be aided by careful definition of terminology and discussion.

UR - http://www.scopus.com/inward/record.url?scp=58949090373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58949090373&partnerID=8YFLogxK

U2 - 10.1002/hep.22620

DO - 10.1002/hep.22620

M3 - Article

C2 - 19085949

AN - SCOPUS:58949090373

VL - 49

SP - 250

EP - 257

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 1

ER -